PropThink: Oral Remodulin Rejection A Broader Problem; Continue To Sell Reuters By Jake King. United Therapeutics Corporation (NADSAQ:UTHR) announced after hours on Tuesday that it's application for an oral formulation of Remodulin (treprostinil) received a Complete Response Letter (CRL) from the FDA. Treprostinil is a treatment ... UPDATE: JP Morgan Downgrades United Therapeutics to Underweight |
Wednesday, October 24, 2012
PropThink: Oral Remodulin Rejection A Broader Problem; Continue To Sell - Reuters
domnaofyvisyhojo.blogspot.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment